Table 4:
First line therapy in children
| low C3 | low C3 | Normal C3 | Normal C3 | P value | |
|---|---|---|---|---|---|
| normal sC5b-9 | high sC5B-9 | normal sC5b-9 | high sC5b-9 | ||
| First line therapy | |||||
| No treatment | 2/12 (17%) | 1/23 (4%) | 1/17 (6%) | 2/7 (29%) | 0.22 |
| Immunosuppresive treatment n (%) | 10/12 (83%) | 22/23 (96%) | 16/17 (94%) | 5/7 (71%) | 0.22 |
| Corticosteroids alone n (%) | 4/12 (33%) | 10/23 (43%) | 9/16 (56%) | 2/5 (40%) | 0.67 |
| Rituximab-based regimen n (%) | 3/12 (25%) | 2/23 (7%) | 0/16 (0%) | 0/5 (0%) | 0.11 |
| Cyclophosphamid-based regimen | 1/12 (8%) | 0/23(0%) | 1/16 (6%) | 0/5 (0%) | 0.53 |
| Mycofenolate mofetil-based regimen n (%) | 2/12 (17%) | 5/23 (22%) | 5/16 (31%) | 2/5 (40%) | 0.68 |
| Monoclonal anti-C5 n (%) | 0/12 (0%) | 6/23 (26%) | 1/16 (6%) | 1/5 (20%) | 0.13 |
| Second line therapy | 3/12 (25%) | 11/23 (48%) | 4/16 (25%) | 1/5 (20%) | 0.33 |
| Monoclonal anti-C5 n (%) | 3/3 (100%) | 8/11 (73%) | 1/16 (6%) | 0/1 | 0.0005 |
| Others n (%) | 0 (0%) | 3/11(27%) | 3/16 (19%) | 1/1 | 0.24 |